Cladribine Venetoclax in Monocytic AML

Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of hypomethylating agent+venetoclax

Trial Details

NCT ID
NCT06232655
Phase
PHASE2
Sponsor
University of Colorado, Denver
Status
RECRUITING
Cancer Type
Hairy Cell Leukemia Leukemia
Interventions
  • Cladribine
  • Venetoclax
  • Azacitidine
Locations (sample)
  • Aurora, Colorado, United States|39.72943,-104.83192

Key Eligibility Criteria

  • A subject will be eligible for study participation if they meet the following criteria within 28 days prior to the first day of treatment. Historic…
  • Subject must have confirmation of non-acute promyelocytic leukemia (APL) Acute Myeloid Leukemia (AML) with a monocytic or monoblastic phenotype or …
  • Note: other prior line(s) of therapy including stem cell transplant (SCT) are allowed, but HMA/Ven must be one of the preceding treatments. Subject…
  • Age ≥ 18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hairy Cell Leukemia Leukemia Trials on Trialify →